Haptoglobin blood assay to assess treatment compliance in rheumatoid arthritis patients treated with tocilizumab

Sirs,

It is currently difficult to guarantee that patients with rheumatoid arthritis (RA) take their treatment correctly. Several studies reported a medication nonadherence in RA patients (1-5). There are no simple biological assays to assess treatment compliance. Measuring drug levels is expensive and difficult to implement in routine care.

A decrease in haptoglobin (HP) levels has been described in a RA patient treated with tocilizumab (TCZ), an effective RA disease-modifying anti-rheumatic drug (6). Based on this case, we retrospectively measured the variation in HP levels in a sample of RA patients treated with subcutaneous (SC) or intravenous (IV) TCZ to determine whether a decrease in HP could be a relevant marker of compliance during RA treatment with TCZ.

RA patients participating in the RCVRIC cohort (PHRC No. 1D-RCB-A01847-40), treated with TCZ and having had at least one HP dosage were included. They were the “RA-TCZ group”. These same 25 patients were their own controls in the “RA-nonTCZ group”. These same 25 patients treated with TCZ and having had at least one HP dosage were included. They were the “RA-TCZ group”. These same 25 patients were their own controls in the “RA-nonTCZ group” because they also received a biotherapy other than TCZ during the RCVRIC follow-up. We collected demographic characteristics, RA activity and biological parameters (HP, CRP), ideally before and after initiation of biotherapies (after 6 months if the data were available, otherwise after 3 or 12 months). We distinguished patients with low HP (level <0.3 g/l) and those with reduced HP (decrease in the HP level under treatment compared to the baseline value).

In the RA-TCZ group (n=25), HP was significantly lower under treatment compared to the baseline level (0.81±1.04 vs. 1.88±1.04 g/l; p<0.001), while the reduction was not significant in the RA-nonTCZ group (1.72±0.82 vs. 1.94±1.03; p=0.06).

In both groups, the decrease in HP was correlated with the decrease in CRP (r²=0.84; p<0.001 in the TCZ group and r²=0.47; p=0.03 in the nonTCZ group) and the decrease in HP was correlated with an increase in haemoglobin level only in the TCZ group (r²=0.55; p=0.006).

Ninety-one per cent of patients (22/24) had a reduction in HP under treatment compared to the before-treatment level (p=0.06). Sensitivity and specificity of HP reduction for patients being treated by TCZ, was respectively 91% and 35%. Six patients (24%) had low HP under treatment in the RA-TCZ group, compared to no patients in the RA-nonTCZ group (p=0.01). Of the 4 RA patients treated with TCZ IV, 3 had a reduced HP (75.0%), while of the 20 treated with TCZ SC, 19 had a reduction in the HP rate (95%).

Of the 15 RA patients who had no systemic inflammation (CRP <5mg/l) at baseline when TCZ was initiated (15/25; 60%), 13 had a decrease of HP level, including 5 with a low HP under treatment.

We observed a greater frequency of reduction in HP level under TCZ SC compared to TCZ IV. This result could be explained by a greater variation in the HP level during IV administration of TCZ, and confirms the interest in monitoring the HP results in RA patients treated with TCZ SC to assess their compliance with the treatment.

The simple measurement of serum haptoglobin seems to be interesting and relevant for assessing compliance with subcutaneous TCZ treatment, especially in the case of a normal CRP level at TCZ initiation. Serum drug levels of TNFi and TCZ would be a more accurate biomarker for compliance, but these measures are not in routine care in all countries and their cost remains higher than the serum HP measurement.

These results need to be confirmed in larger cohorts of patients treated by TCZ, but no change in the haptoglobin level compared to the before-treatment level nor decrease under TCZ treatment seems to suggest dissatisfaction treatment compliance.

P.-Y. MONTAGNON

M. BEAUGER

M. COUDERC, MD

A. Tournadre, MD, PhD

M. SOUBRIER, MD, PhD

S. MATHIEU, MD, PhD

Rheumatology Department,
Gabriel Montpied Teaching Hospital,
Clermont-Ferrand, France.

Please address correspondence to:
Sylvain Mathieu
Rheumatology Department, Centre Hospitalier Universitaire Gabriel Montpied,
58 Rue Montalembert,
63003 Clermont-Ferrand, France.
E-mail: smathieu@chu-clermontferrand.fr

Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2024.

References


Table I. Comparison of tocilizumab and other biotherapies RA patients.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Tocilizumab RA patients n=25</th>
<th>Other biotherapies RA patients n=25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>55.7±9.5</td>
<td>60.3±11.5</td>
</tr>
<tr>
<td>Women, %</td>
<td>21%, 84%</td>
<td>21%, 84%</td>
</tr>
<tr>
<td>BMI</td>
<td>25.6±4.9</td>
<td>12.4%</td>
</tr>
<tr>
<td>IV route, n, %</td>
<td>5, 20%</td>
<td>4.41±1.09</td>
</tr>
<tr>
<td>DAS28</td>
<td>4.27±1.14</td>
<td>1.94±1.03</td>
</tr>
<tr>
<td>CDAI</td>
<td>19.0±8.5</td>
<td>3.76±1.25</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>17.0±26.4</td>
<td>14.3±8.7</td>
</tr>
<tr>
<td>RBC, Giga/l</td>
<td>4.51±0.38</td>
<td>15.6±19.2</td>
</tr>
<tr>
<td>Haemoglobin, g/dl</td>
<td>13.2±1.2</td>
<td>13.1±1.6</td>
</tr>
<tr>
<td>Haptoglobin, g/l</td>
<td>1.88±1.04</td>
<td>1.72±0.82</td>
</tr>
</tbody>
</table>

RA: rheumatoid arthritis; BMI: Body Mass Index; IV: intravenous; DAS: Disease Activity Score; CRP: C-reactive protein; CDAI: Clinical Disease Activity Index; RBC: red blood cell count. Values are mean ± standard deviation.